Chemomab Therapeutics Statistics Share Statistics Chemomab Therapeutics has 1.16M
shares outstanding. The number of shares has increased by 12.04%
in one year.
Shares Outstanding 1.16M Shares Change (YoY) 12.04% Shares Change (QoQ) 12% Owned by Institutions (%) 0.57% Shares Floating 991.34K Failed to Deliver (FTD) Shares 2,426 FTD / Avg. Volume 1.75%
Short Selling Information The latest short interest is 141.57K, so 0.75% of the outstanding
shares have been sold short.
Short Interest 141.57K Short % of Shares Out 0.75% Short % of Float 0.76% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -9.32 and the forward
PE ratio is -16.8.
Chemomab Therapeutics's PEG ratio is
0.15.
PE Ratio -9.32 Forward PE -16.8 PS Ratio 0 Forward PS 0.2 PB Ratio 9.6 P/FCF Ratio -8.45 PEG Ratio 0.15
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Chemomab Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.98,
with a Debt / Equity ratio of 0.02.
Current Ratio 4.98 Quick Ratio 4.98 Debt / Equity 0.02 Debt / EBITDA -0.02 Debt / FCF -0.02 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-697.25K Employee Count 20 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -34.16% in the
last 52 weeks. The beta is 0.52, so Chemomab Therapeutics's
price volatility has been higher than the market average.
Beta 0.52 52-Week Price Change -34.16% 50-Day Moving Average 3.2 200-Day Moving Average 5.13 Relative Strength Index (RSI) 64.75 Average Volume (20 Days) 138,327
Income Statement
Revenue n/a Gross Profit -53.25K Operating Income -14.74M Net Income -13.95M EBITDA -13.96M EBIT -14.01M Earnings Per Share (EPS) -0.78
Full Income Statement Balance Sheet The company has 6.07M in cash and 324K in
debt, giving a net cash position of 5.75M.
Cash & Cash Equivalents 6.07M Total Debt 324K Net Cash 5.75M Retained Earnings -102.62M Total Assets 11.13M Working Capital 9.18M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -15.46M
and capital expenditures 4.96, giving a free cash flow of -15.39M.
Operating Cash Flow -15.46M Capital Expenditures 4.96 Free Cash Flow -15.39M FCF Per Share -0.86
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields CMMB does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CMMB is $26.5,
which is 668.1% higher than the current price. The consensus rating is "Strong Buy".
Price Target $26.5 Price Target Difference 668.1% Analyst Consensus Strong Buy Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 26, 2025. It was a
backward
split with a ratio of 1:4.
Last Split Date Aug 26, 2025 Split Type backward Split Ratio 1:4
Scores Altman Z-Score -14.99 Piotroski F-Score 3
